title: Proliferation-associated nucleolar antigen P120: a prognostic marker in node-negative breast cancer.
abstract: BACKGROUND
  P120 is a nucleolar proliferation antigen found in rapidly dividing cells and in a variety of malignancies.
  
  
  METHODS
  Our purpose was to determine whether P120 expression is a prognostic factor for patients with node-negative breast cancer by testing pathologic material from 90 patients for P120 immunoreactivity, histologic grade, and estrogen receptors.
  
  
  RESULTS
  P120 was detected in 52 of the 90 specimens (58%). Node-negative cancer patients with tumors that did not express the P120 antigen had a significantly better overall survival rate than node-negative cancer patients with tumors that did express P120 (92% vs 69%; p = 0.035). Histologic studies indicated that 36 tumors were grade I, 28 were grade II, and 26 were grade III. The presence of P120 correlated significantly with the nuclear grade of the tumor: 73% of grade III tumors, 64% of grade II tumors, and 42% of grade I tumors stained positive for P120 (p = 0.033). The correlation between nuclear grade and overall survival rate was also significant (grade 1, 94%; grade II, 79%; grade III, 58%); (p = 0.003). No significant correlation was found between P120 expression and estrogen receptors. Multivariate analysis shows that P120 expression and histologic grade together are the strongest predictors of survival.
  
  
  CONCLUSIONS
  The biologic marker P120 may play an important role in determining which patients with node-negative cancer will benefit most from adjuvant therapy.
authors.affiliation: Department of Surgery, University of Kentucky Chandler Medical Center, Lexington 40536-0084.
authors.forename: P C
authors.initials: PC
authors.lastname: McGrath
authors.forename: D T
authors.initials: DT
authors.lastname: Holley
authors.forename: L S
authors.initials: LS
authors.lastname: Hamby
authors.forename: D E
authors.initials: DE
authors.lastname: Powell
authors.forename: C
authors.initials: C
authors.lastname: Mattingly
authors.forename: J W
authors.initials: JW
authors.lastname: Freeman
mesh_terms: D000951:Antigens, Neoplasm / Q000032:analysis*; D014408:Biomarkers, Tumor / Q000032:analysis*; D001943:Breast Neoplasms / Q000737:chemistry* / Q000401:mortality / Q000473:pathology; D005260:Female; D005434:Flow Cytometry; D006801:Humans; D008207:Lymphatic Metastasis; D009687:Nuclear Proteins / Q000032:analysis*; D011379:Prognosis; D018809:Proliferating Cell Nuclear Antigen / Q000032:analysis; D011960:Receptors, Estrogen / Q000032:analysis; D012044:Regression Analysis; D015996:Survival Rate; D012359:tRNA Methyltransferases
chemical_list: D000951:Antigens, Neoplasm; D014408:Biomarkers, Tumor; D009687:Nuclear Proteins; D018809:Proliferating Cell Nuclear Antigen; D011960:Receptors, Estrogen; C065028:NOP2 protein, human; D012359:tRNA Methyltransferases